IL312157A - History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors - Google Patents
History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitorsInfo
- Publication number
- IL312157A IL312157A IL312157A IL31215724A IL312157A IL 312157 A IL312157 A IL 312157A IL 312157 A IL312157 A IL 312157A IL 31215724 A IL31215724 A IL 31215724A IL 312157 A IL312157 A IL 312157A
- Authority
- IL
- Israel
- Prior art keywords
- dyrk1a
- pyrrolo
- inhibitors
- triazines derivatives
- triazines
- Prior art date
Links
- 101150086683 DYRK1A gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- KGRPHHFLPMPUBB-UHFFFAOYSA-N pyrrolo[2,1-f][1,2,4]triazine Chemical class C1=NC=NN2C=CC=C21 KGRPHHFLPMPUBB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254733P | 2021-10-12 | 2021-10-12 | |
| US202263347757P | 2022-06-01 | 2022-06-01 | |
| PCT/US2022/046416 WO2023064366A1 (en) | 2021-10-12 | 2022-10-12 | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312157A true IL312157A (en) | 2024-06-01 |
Family
ID=84330173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312157A IL312157A (en) | 2021-10-12 | 2022-10-12 | History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12134625B2 (enExample) |
| EP (1) | EP4415816B1 (enExample) |
| JP (1) | JP2024539620A (enExample) |
| KR (1) | KR20240089275A (enExample) |
| AU (1) | AU2022367222A1 (enExample) |
| CA (1) | CA3234831A1 (enExample) |
| IL (1) | IL312157A (enExample) |
| MX (1) | MX2024004552A (enExample) |
| PY (1) | PY2289204A (enExample) |
| TW (1) | TW202322800A (enExample) |
| UY (1) | UY39979A (enExample) |
| WO (1) | WO2023064366A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508323A (ja) * | 2022-01-25 | 2025-03-26 | キネート バイオファーマ インク． | Ｃｄｋ４／６キナーゼの阻害薬 |
| JP2025538866A (ja) * | 2022-11-03 | 2025-12-02 | バイオスプライス セラピューティクス インコーポレイテッド | ４－アミノピロロ［２，１－ｆ］［１，２，４］トリアジンと、その調製物及び使用 |
| WO2024211797A1 (en) * | 2023-04-07 | 2024-10-10 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| CN119019402A (zh) * | 2023-05-24 | 2024-11-26 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 |
| IL326145A (en) * | 2023-07-26 | 2026-03-01 | Khora Spv 1 Llc | CDK2/4/6 kinase inhibitors |
| US20250206746A1 (en) * | 2023-12-22 | 2025-06-26 | Biosplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| US7507826B2 (en) | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| WO2006079055A2 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| JP2018526452A (ja) * | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Ｄｙｒｋ１ａの小分子抑制剤およびその使用 |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| WO2019074962A1 (en) * | 2017-10-10 | 2019-04-18 | Syros Pharmaceuticals, Inc. | PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES |
| JP7487170B2 (ja) | 2018-03-01 | 2024-05-20 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | 毒性小胞体ストレスを抑制するための化合物、組成物および方法 |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2020006115A1 (en) | 2018-06-26 | 2020-01-02 | Betty Tam | Methods of treating cancer using a clk inhibitor |
| AU2019362849B2 (en) | 2018-10-16 | 2025-06-05 | Dana-Farber Cancer Institute, Inc. | Azaindole inhibitors of wild-type and mutant forms of LRRK2 |
| WO2020150552A2 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| KR20230079003A (ko) | 2020-07-20 | 2023-06-05 | 니도 바이오사이언시스, 인코포레이티드 | 안드로겐 수용체 조절제로서의 인돌 화합물 |
| CA3234937A1 (en) | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors |
| EP4415817A1 (en) | 2021-10-12 | 2024-08-21 | BioSplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| JP2025525391A (ja) | 2022-06-23 | 2025-08-05 | バイオスプライス セラピューティクス インコーポレイテッド | ４－アルコキシピロロ［２，１－ｆ］［１，２，４］トリアジンならびにその製剤及び使用 |
-
2022
- 2022-10-12 UY UY0001039979A patent/UY39979A/es unknown
- 2022-10-12 PY PY202202289204A patent/PY2289204A/es unknown
- 2022-10-12 CA CA3234831A patent/CA3234831A1/en active Pending
- 2022-10-12 MX MX2024004552A patent/MX2024004552A/es unknown
- 2022-10-12 IL IL312157A patent/IL312157A/en unknown
- 2022-10-12 TW TW111138697A patent/TW202322800A/zh unknown
- 2022-10-12 AU AU2022367222A patent/AU2022367222A1/en active Pending
- 2022-10-12 JP JP2024522052A patent/JP2024539620A/ja active Pending
- 2022-10-12 US US17/964,489 patent/US12134625B2/en active Active
- 2022-10-12 EP EP22801289.4A patent/EP4415816B1/en active Active
- 2022-10-12 WO PCT/US2022/046416 patent/WO2023064366A1/en not_active Ceased
- 2022-10-12 KR KR1020247014718A patent/KR20240089275A/ko active Pending
-
2024
- 2024-08-15 US US18/806,231 patent/US20250171466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024539620A (ja) | 2024-10-29 |
| US20250171466A1 (en) | 2025-05-29 |
| US12134625B2 (en) | 2024-11-05 |
| EP4415816B1 (en) | 2026-03-18 |
| US20230312605A1 (en) | 2023-10-05 |
| MX2024004552A (es) | 2024-06-04 |
| UY39979A (es) | 2023-04-14 |
| TW202322800A (zh) | 2023-06-16 |
| CA3234831A1 (en) | 2023-04-20 |
| PY2289204A (es) | 2023-12-05 |
| AU2022367222A1 (en) | 2024-05-02 |
| WO2023064366A1 (en) | 2023-04-20 |
| EP4415816A1 (en) | 2024-08-21 |
| KR20240089275A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4077328A4 (en) | PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS | |
| IL302820B1 (en) | Tricyclic carboxamide derivatives as PRMT5 inhibitors | |
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| SG10201804791UA (en) | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| AU2012204982A8 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
| IL321144A (en) | History of N-phenyl-pyrazolo[5,1-A]pyridine-3-carboxamide as wild-type C-KIT kinase inhibitors for the treatment of erectile dysfunction | |
| IL288529A (en) | History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy | |
| IL310403A (en) | Converted pyridine derivatives as SARM1 inhibitors | |
| WO2010144499A3 (en) | Urea derivatives as kinase inhibitors | |
| IL306065A (en) | Uracil history as TRPA1 inhibitors | |
| IL319011A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| IL319009A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| IN2012DN01642A (enExample) | ||
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| HK40115098A (en) | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| IL306008A (en) | Pyrimidine derivatives are useful as LRRK2 kinase inhibitors | |
| WO2014062852A3 (en) | Thiohydantoin derivatives and uses thereof | |
| HK40118483A (en) | Heterocyclic compounds as pi3ka inhibitors | |
| CA3297023A1 (en) | Triazine derivatives as nlrp3 inhibitors | |
| AU2024307670A1 (en) | Triazine derivatives as nlrp3 inhibitors |